A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. - Wikidata - awgldk - TriplyDB

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

http://www.wikidata.org/entity/Q37378350

about

Lupus nephritis: current update Immunotherapy of systemic sclerosis Belimumab in systemic lupus erythematosus Use of biologics in SLE: a review of the evidence from a clinical perspective B-cell survival factors in autoimmune rheumatic disorders The rationale for BAFF inhibition in systemic lupus erythematosus Profile of atacicept and its potential in the treatment of systemic lupus erythematosus New autoantibody detection technologies yield novel insights into autoimmune disease A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis Patient-reported outcomes in lupus clinical trials with biologics.Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.Hematological disorders in patients with systemic lupus erythematosus.Reduced tumour necrosis factor receptor superfamily 13C inversely correlated with tumour necrosis factor superfamily 13B in patients with immune thrombocytopenia.Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future Antibodies to watch in 2010 Health-related quality of life and employment among persons with systemic lupus erythematosus.Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.Advances in drug therapy for systemic lupus erythematosus.Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.Lupus nephritis: lessons from murine models BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus.Clearance of pathological antibodies using biomimetic nanoparticles.BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.Efficacy and safety data of belimumab in patients with systemic lupus erythematosus.Belimumab for the treatment of systemic lupus erythematosus.Treatment of systemic lupus erythematosus with epratuzumab.Current and novel therapeutics in the treatment of systemic lupus erythematosus Renal involvement in autoimmune connective tissue diseases.Biologic therapy for autoimmune diseases: an update.B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity.Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100.Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies.Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors.Advances in phage display technology for drug discovery.Cytokine disturbances in systemic lupus erythematosus.

P2860

Q22000837-6BEE5F49-9540-464C-8908-19CAC2C8EAEA Q24634395-2E264746-B65E-4C25-8BC5-E6D145605C3A Q26778277-DE996C69-7BAB-4C10-B3ED-1A92D3B6ED88 Q26783652-AE5A4DB2-7C6E-4861-97F0-1CD1CABCABCE Q26796484-11C2C1F4-BC82-4E7C-BA41-B6018B5DEF4C Q26827373-63C11277-F62F-410C-A76C-86CD06A25090 Q26849719-CDFFD174-0F4C-4264-8423-D81115C14878 Q27000173-08895411-3F8B-4754-9A4D-BA254FA86410 Q28254310-D43DB96B-663D-4E81-9E33-D650D20D4C0A Q28676968-BF9F12BF-16AC-468F-881D-E91B8BC274AC Q30391564-5A7AE1A9-496A-45A6-BFE4-0AC5BA74AEF4 Q30580226-8ECFC929-198E-4B93-AC95-7CF287AA52F5 Q33411323-6D8F7940-4BAA-4286-BD2E-EA7B291F7483 Q33415681-2EDF43F4-4189-422D-92C9-06663C1BE0B0 Q33601679-9CAE421A-0AE7-4854-9492-950CB041B036 Q33688243-CB170FC0-3F90-4FBA-8948-9EBCF14EE2F4 Q33708268-470915E2-7227-44B5-9E11-DBD1ED3248B0 Q33731705-25018C48-0ED4-4ACE-B831-C782D3AECC29 Q33757883-40C28FC7-DFDD-44C2-9231-B89684A7EDA4 Q33803763-B9F97358-FE4D-4547-B748-0D6E633B6EDC Q33998360-870F7FE0-8D02-41AD-AFCE-84EA55F716CC Q34012753-00D1A5FA-17D5-4B7A-8849-45780FCAFCE6 Q34114253-CEBA23AA-FAD1-4153-BBFD-A6C264C52B43 Q34218004-349AC2CE-437A-49E1-A0CC-96197B04581F Q34245983-6372D735-A733-4024-A040-0D8581F716E9 Q34369628-E985997F-1230-4CB9-B630-8BE41206A026 Q34455827-CC2B2DD8-F0B5-438B-85E3-6D87BD2506E5 Q34580559-A055D758-CFDA-495B-BD43-04C0C275DBC1 Q34648851-307197CE-4517-4EF1-8480-034A7816829E Q34654954-30555B31-C3BE-4D31-A7DD-47C483BDC99C Q34655597-F6C98595-4F14-43F4-91A9-392A16767F71 Q34781487-F4552546-CAD9-460B-8F0B-A26A38ED600F Q34810293-E39A3063-4EEA-4025-9EAC-2752779A606B Q35031692-E408C87F-7295-4A13-AD3D-530A962BF6C1 Q35062895-D3E839CC-AB14-48AA-8A9A-E12EBF4992E1 Q35309470-8CF5BD92-53E7-48B0-B4CF-6A589CA75FDF Q35456519-598AAF99-42AF-455A-A833-3DCAB7374114 Q35544326-8602AA90-9869-46E6-ACDA-BDDFCFE49D82 Q35614190-0388EF2C-8A78-43FC-9703-FC8B0C9407FE Q35617573-1C0CEC35-CC9E-4E17-8EC5-F2993D996305

P2860

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

http://www.wikidata.org/entity/Q37378350

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A phase II, randomized, double ...... systemic lupus erythematosus.

@en

A phase II, randomized, double ...... systemic lupus erythematosus.

@nl

type

label

A phase II, randomized, double ...... systemic lupus erythematosus.

@en

A phase II, randomized, double ...... systemic lupus erythematosus.

@nl

prefLabel

A phase II, randomized, double ...... systemic lupus erythematosus.

@en

A phase II, randomized, double ...... systemic lupus erythematosus.

@nl

P1433

Q37378350-A032B318-0DEB-4430-BF41-3E7E3C0D46D5

P1476

Q37378350-AA5BC638-DFC8-42D1-90C5-4F2EBC8623A1

P2093

Q37378350-2FB74698-3D65-4D23-887D-69777953B835

Q37378350-5CD74D3F-77DE-49E9-A536-9B542E9FFD62

Q37378350-783945FF-C527-4353-8DCF-DB7D3ABE2E7E

Q37378350-8196271B-B899-48A9-968B-67428B7D3D07

Q37378350-8F1A0A66-5F37-40DF-866D-E012612507AB

Q37378350-9F3141B0-2026-42E2-8FE2-9957B25ADD93

Q37378350-B4BE8722-6729-4D88-AF52-137F30BF2D5B

Q37378350-DAC25611-B96D-42BB-85D2-E2959EC24DF4

Q37378350-E6EB683B-8219-4817-94F2-EE762AE92EE1

Q37378350-E763437F-B30D-43AA-9250-DDBED204009E

P2860

Q37378350-0B0ABBF1-4D52-48CE-B707-032023F2EAAB

Q37378350-1568F26F-7257-4419-8B3B-B683E64E4B1E

Q37378350-20539B54-B433-4259-A368-2FDBDE177118

Q37378350-2AAD5B7C-1463-428A-B06C-1CAB5449D093

Q37378350-2AF6FE72-1E30-44B1-AF8F-8CDAE4F9B760

Q37378350-331F12F2-8251-4909-873C-667CD4A8C5EB

Q37378350-33DD49B1-477A-4932-8657-F44D56023D25

Q37378350-51A7F91F-E0C7-4CD4-8E07-85E8216448BA

Q37378350-52D8EB55-E161-4FCE-9BF4-F7B26A798C63

Q37378350-531CF4B0-2A1A-45EA-915D-707A8D7A63E2

P304

Q37378350-F937C1B8-3D64-4ED3-AF44-129AF815A7C2

P31

Q37378350-60ED53F7-1539-4FF9-B306-7DDD6B6457EF

P356

Q37378350-8F1AF009-9B8D-4B90-84A7-5D69C4493A92

P433

Q37378350-D253B57A-888A-4595-BA1D-9265F775F80E

P478

Q37378350-486F9257-1D99-4B9F-8DB2-43C16CB114BB

P50

Q37378350-5853732F-2123-468C-9C76-4B4FF12F0673

P577

Q37378350-3C04C106-5EA2-4A20-85AF-00B557CD9BA9

P5875

Q37378350-BFA5E495-1159-42A3-807D-46A6918E530C

P698

Q37378350-0B5A2DD6-FC48-4B36-AB79-7C4E510E40AC

P921

Q37378350-0F18A1EF-B94B-4A01-B262-9C2C944AF5F6

Q37378350-50E3C029-4BC1-4141-B8B4-2B5DE8854092

P932

Q37378350-93231DEE-DCC1-4944-B7D0-F2BB1D417CAF

P356

P1433

Arthritis & Rheumatology

P1476

A phase II, randomized, double ...... systemic lupus erythematosus.

@en

P2093

Daniel J Wallace

http://www.w3.org/2001/XMLSchema#string

Ellen M Ginzler

http://www.w3.org/2001/XMLSchema#string

James D McKay

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Lisse

http://www.w3.org/2001/XMLSchema#string

Joan T Merrill

http://www.w3.org/2001/XMLSchema#string

Marc R Chevrier

http://www.w3.org/2001/XMLSchema#string

Richard A Furie

http://www.w3.org/2001/XMLSchema#string

Vivian Fernandez

http://www.w3.org/2001/XMLSchema#string

W Joseph McCune

http://www.w3.org/2001/XMLSchema#string

W Winn Chatham

http://www.w3.org/2001/XMLSchema#string

P2860

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

BCMA is essential for the survival of long-lived bone marrow plasma cells

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.

P304

1168-1178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.24699

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Michelle A. Petri

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26774426

http://www.w3.org/2001/XMLSchema#string

P698

19714604

http://www.w3.org/2001/XMLSchema#string

P921

P932

2758229

http://www.w3.org/2001/XMLSchema#string